Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Completed 39Terminated 23Recruiting 21Unknown 13Withdrawn 6Not yet recruiting 6Active not recruiting 5Suspended 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Pancreatic Neoplasms 27Carcinoma, Non-Small-Cell Lung 15Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Carcinoma, Hepatocellular 5Sarcoma 4Neoplasm Metastasis 4Bone Neoplasms 4Recurrence 3Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Histiocytoma, Malignant Fibrous 3Dermatofibrosarcoma 3Biliary Tract Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms, Unknown Primary 2Lymphoma, T-Cell 2Lymphoma, B-Cell 2Liposarcoma 2Leiomyosarcoma 2Hodgkin Disease 2Hemangiosarcoma 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

Gemcitabine 6Cisplatin 5infigratinib 2Platinum 2Fluorouracil 21,2-diaminocyclohexaneplatinum II citrate 2ricolinostat 1niraparib 1lenvatinib 1galactomannan 1fludarabine 1famitinib 1dostarlimab 1atezolizumab 1aldesleukin 1Taxes 1Standard of Care 1Sildenafil Citrate 1Sevoflurane 1Photochemotherapy 1Oxaliplatin 1Observation 1NVP-BKM120 1Interviews as Topic 1IMC-001 1Electroporation 1Desflurane 1Cyclophosphamide 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Cholangiocarcinoma × Gemcitabine × Clear all
NCT05514912 2023-12-26

Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial

Emory University

Phase 2 Withdrawn
Gastrointestinal

Cholangiocarcinoma

NCT04546828 2022-06-15

A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea

Samsung Medical Center

Phase 2 Withdrawn
Gastrointestinal

Cholangiocarcinoma

NCT04480190 2022-04-20

Neoadjuvant Therapy in Biliary Adenocarcinoma

University of Cincinnati

Phase 1 Withdrawn
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03081039 2018-02-19

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

University of Louisville

Phase 3 Withdrawn
Gastrointestinal

Cholangiocarcinoma

NCT02856568 2017-05-30

Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma

Mayo Clinic

Phase 1 Withdrawn
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT00713687 2012-08-10

GemOx-PDT

Technical University of Munich

Phase 2 Withdrawn
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡